Annual Meeting of Stockholders - RESMED INC
- Financial Performance:
- Core business revenue grew 7% in constant currency year-over-year for the first quarter.
- Non-GAAP earnings per share (EPS) increased by 14%, representing double the revenue growth rate.
- Gross profit margins improved by 50 basis points compared to the prior year.
- Generated significant free cash flow, with over $1 billion returned to shareholders via a $936 million share buyback (including ASR) and dividends.
- Guidance and Future Outlook:
- Management targets double-digit annual growth through 2030.
- Long-term goal to expand impact from the current 162 million lives changed in the last 12 months to 500 million lives by 2030.
- Acquired product "Nedra" for Restless Leg Syndrome (RLS) is projected to grow from $20 million in revenue last year to $34 million this year.
- Anticipates sustained momentum from large pharmaceutical partnerships driving demand for sleep therapy among patients on glucagon-like peptide (GLP) products.
- Business Segments and Product Lines:
- Digital Health: Maintains the largest medtech digital ecosystem with 36 million cloud-connected devices, 39 million patients, and 29 billion nights of respiratory data.
- Supply & Accessories: Launched "Equipment Care" feature in MyAir app to proactively manage patient equipment resupply; GLP-linked patients show 11% higher therapy initiation, 3% higher 1-year resupply, and >7% higher 3-year resupply rates.
- Product Innovation: Fabric masks (AirTouch N30i, AirTouch F40) demonstrate 6% higher adherence rates compared to silicone equivalents.
- Inorganic Growth: Introduced Nedra, a non-invasive nerve stimulation device for RLS targeting 400 million potential users globally via VA and DME channels.
- Market and Competitive Landscape:
- Operates in a Total Addressable Market (TAM) of 2.7 billion people suffering from sleep apnea, insomnia, RLS, and COPD.
- Leverages unique scale advantage with operations in 144 countries.
- Sees a "once-in-a-generation" demand generation opportunity driven by the mainstreaming of primary care visits for GLP-based treatments.
- Management describes the company's trajectory as resembling its pre-IPO 1994 position with strong organic growth capabilities.
- Risks and Challenges:
- No specific financial or operational risks were detailed in this specific transcript, which focused primarily on an Annual General Meeting (AGM) update.
- Challenges implicit in the strategy include the integration and scaling of the newly acquired Nedra platform and maintaining adherence rates as the patient base grows.
- Management Commentary and Tone:
- Tone was highly confident and optimistic, characterizing the company as a "compelling investment opportunity" with high ROI.
- Management emphasized the dual focus on changing lives and delivering financial returns, citing strong capital allocation discipline.
- CEO Mick Farrell noted that the company is self-funding growth and does not require external capital for new initiatives.
- Analyst Questions and Answers:
- The Q&A session was conducted among shareholders during the virtual meeting.
- No questions were submitted by shareholders during the designated Q&A period.
- Other Key Points:
- This transcript is from the 2026 Annual General Meeting of Stockholders, held virtually.
- Shareholder proposals (director elections, auditor ratification, executive compensation) were unanimously approved.
- The meeting confirmed the election of 10 directors, including CEO Michael Farrell and Founder Peter Farrell.
- Management declined to provide new material public information beyond what was in recent earnings reports, focusing the update on strategic progress and product velocity.
- Company
- RESMED INC
- Keywords
- RESMED INC